Lilly has lost the latest round in an enduring legal fight over patents casing the administration of vitamins in conjunction with its epic lung cancer drug, Alimta (pemexetred). According to UK High Court, Lilly’s Alimta vitamin regimen patent would not be infringed by Allergan marketing its drug in the UK, France, Italy and Spain with instructions to dilute the product only with dextrose solution. [more]
Kommentare